The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
A bipartisan group of state health policymakers from both the executive and legislative branches who are focused on improving population health.
Networks of state officials, advocates, and others aiming to invest in and transform primary care.
A program dedicated to advancing state-based efforts to make health care more affordable for residents, employers, and states.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
A leadership development program for early and mid-career state government officials who are committed to improving the health of all people in their communities.
A leadership program for senior state government officials who are committed to improving population health.
The Fund focuses on creating an affordable health care system built on strong primary care and partnerships that improve health outcomes for all.
Improving state leaders’ ability to enact and implement evidence-based health policies.
Advancing policies that create a more prevention- and primary care-oriented health system.
Improving population health through policies that contain health care cost growth.
Our state health policy resources offer relevant data analysis and best practices.
The Fund publishes reports, issues briefs, and case studies on state health policy issues.
Short takes on health policy issues from Milbank staff and guest authors.
Insights from Milbank President Debra Lubar on state health policymaking.
Reported articles and Q&As on timely health policy issues, as well as foundation updates.
Milbank Memorial Fund and Milbank Quarterly webinars featuring state health policymakers and researchers.
Updates and expert contact information for reporters.
The Milbank Memorial Fund is a private foundation that works to improve population health and health equity.
Quarterly Topic
Quarterly Article
May 2022 Huseyin Naci, Ilias Kyriopoulos, William B. Feldman, Thomas J. Hwang, Aaron S. Kesselheim, Amitabh Chandra,
This study finds that newly approved drugs are frequently subject to formulary exclusions and restrictions such as prior authorization in Medicare Part D plans. More
March 2022 Julie Donohue, PhD,
In 1993, Stephen Soumerai and coauthors published “A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of… More
March 2022 Lindor Qunaj, Anna Kaltenboeck, Peter B. Bach,
This study by Lindor Qunaj of Montefiore Medical Center and colleagues finds that compulsory licensing, a practice whereby national authorities can enable the production of a generic before the original patent expires, is rarely used to address drug prices and, when used, is unlikely to contribute to price discounts. More
August 2021 Liam Bendicksen, Benjamin N. Rome, Jerry Avorn, Aaron S. Kesselheim,
Context: Rising prescription drug costs are consuming a growing proportion of state and private budgets. In response, lawmakers have experimented with… More
June 2021 Richard G. Frank, Thomas G. McGuire, Ian Nason,
Context: The image of generic drugs as a commodity sold in competitive markets is an oversimplification, as evidenced by increasing accounts of price… More
April 2021 George Maliha, Sara Gerke, I. Glenn Cohen, Ravi B. Parikh,
After more than a decade of promise and hype, artificial intelligence (AI) and machine learning (ML) are finally making inroads into clinical… More
October 2020 Maximilian Salcher-Konrad, Huseyin Naci, Courtney Davis,
Context: Regulatory agencies are increasingly required to make market approval decisions for new drugs on the basis of limited clinical evidence, a… More
December 2019 Amanda I. Mauri, Tarlise N. Townsend, Rebecca L. Haffajee,
States have implemented a number of preventive measures to address the health consequences of opioid misuse and addiction. In a new review of evaluations of these policies, the University of Michigan’s Amanda Mauri and colleagues conclude that robust prescription drug monitoring programs reduce opioid prescribing if they include features like requiring practitioners to check an electronic database before prescribing and obtaining prior authorization for high-risk opioids. More